Free Trial

Zai Lab (ZLAB) Projected to Post Earnings on Thursday

Zai Lab logo with Medical background

Zai Lab (NASDAQ:ZLAB - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $118.40 million for the quarter. Zai Lab has set its FY 2025 guidance at EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

NASDAQ:ZLAB traded down $1.09 during trading hours on Tuesday, reaching $29.86. The company's stock had a trading volume of 344,868 shares, compared to its average volume of 1,071,171. The firm has a 50-day simple moving average of $33.12 and a 200-day simple moving average of $29.77. Zai Lab has a 1 year low of $16.01 and a 1 year high of $39.77. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of -10.78 and a beta of 1.04.

Insider Buying and Selling

In other news, insider Rafael Amado sold 3,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $38.41, for a total value of $115,230.00. Following the completion of the transaction, the insider now owns 30,834 shares of the company's stock, valued at approximately $1,184,333.94. This represents a 8.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Frazor Titus Edmondson III sold 14,544 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $32.98, for a total value of $479,661.12. Following the completion of the transaction, the insider now owns 14,328 shares of the company's stock, valued at approximately $472,537.44. The trade was a 50.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 138,744 shares of company stock valued at $4,685,294 over the last quarter. 13.88% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, March 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Scotiabank assumed coverage on shares of Zai Lab in a report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price target for the company. Finally, Bank of America reissued a "neutral" rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd.

Read Our Latest Report on Zai Lab

Zai Lab Company Profile

(Get Free Report)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

Featured Articles

Earnings History for Zai Lab (NASDAQ:ZLAB)

Should You Invest $1,000 in Zai Lab Right Now?

Before you consider Zai Lab, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.

While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines